NUMORPHAN Drug Patent Profile
✉ Email this page to a colleague
When do Numorphan patents expire, and what generic alternatives are available?
Numorphan is a drug marketed by Endo Pharms and is included in one NDA.
The generic ingredient in NUMORPHAN is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Numorphan
A generic version of NUMORPHAN was approved as oxymorphone hydrochloride by IMPAX LABS on June 14th, 2010.
Summary for NUMORPHAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 30 |
Clinical Trials: | 3 |
Patent Applications: | 4,756 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NUMORPHAN at DailyMed |
Recent Clinical Trials for NUMORPHAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Early Phase 1 |
M.D. Anderson Cancer Center | Early Phase 1 |
Endo Pharmaceuticals | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for NUMORPHAN
US Patents and Regulatory Information for NUMORPHAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharms | NUMORPHAN | oxymorphone hydrochloride | SUPPOSITORY;RECTAL | 011738-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |